Mantle cell lymphoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Farima Kahe (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
[[Mantle cell lymphoma]] accounts for 4–8% of all adult [[Non-Hodgkin lymphoma|non- | [[Mantle cell lymphoma]] accounts for 4–8% of all adult [[Non-Hodgkin lymphoma|non-Hodgkin lymphoma]] (NHL). It has an [[incidence]] of approximately 1-2/100000 and tends to occur more in [[males]], Caucasian race, with a median [[age]] of about 60 years. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Revision as of 04:42, 3 January 2019
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma epidemiology and demographics |
|
Mantle cell lymphoma epidemiology and demographics in the news |
|
Risk calculators and risk factors for Mantle cell lymphoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]
Overview
Mantle cell lymphoma accounts for 4–8% of all adult non-Hodgkin lymphoma (NHL). It has an incidence of approximately 1-2/100000 and tends to occur more in males, Caucasian race, with a median age of about 60 years.
Epidemiology and Demographics
Incidence
- The annual incidence of mantle cell lymphoma has increased during recent decades to 1–2/100 000 recently.[1]
Age
- The median age at diagnosis for mantle cell lymphoma is about 60 years.[2]
Race
- Mantle cell lymphoma tends to affect Caucasians more than African-Americans.[3]
Gender
- Males are more commonly affected by mantle cell lymphoma than females. The male to female ratio is approximately 4 to 1.[4]
References
- ↑ M. Dreyling, C. Geisler, O. Hermine, H. C. Kluin-Nelemans, S. Le Gouill, S. Rule, O. Shpilberg, J. Walewski & M. Ladetto (2014). "Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of oncology : official journal of the European Society for Medical Oncology. 25 Suppl 3: iii83–iii92. doi:10.1093/annonc/mdu264. PMID 25210087. Unknown parameter
|month=ignored (help) - ↑ Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter
|month=ignored (help) - ↑ Yuhong Zhou, Haijun Wang, Wenjing Fang, Jorge E. Romaguer, Yanxia Zhang, Kay B. Delasalle, Larry Kwak, Qing Yi, Xianglin L. Du & Michael Wang (2008). "Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004". Cancer. 113 (4): 791–798. doi:10.1002/cncr.23608. PMID 18615506. Unknown parameter
|month=ignored (help) - ↑ Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter
|month=ignored (help)